Truist Securities maintains Tenet Healthcare at Buy, raises price target to $305 from $290

Truist Securities reaffirmed its Buy rating for Tenet Healthcare and increased its price target to $305, up from $290. This target suggests a 13.4% upside from the stock's Nov 2 close. Other recent analyst price targets for Tenet range from $300 to $342.

Original reporting
Published Nov 3, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 5:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Truist Securities maintains Tenet Healthcare at Buy, raises price target to $305 from $290 — source image
Decision brief

The 30-second read

$THCBullishLow
01

Why it matters

A higher target can influence short-term positioning and sentiment, but without new company-specific disclosures it is unlikely to be a primary driver of fundamentals.

02

Market read

Valuation expectations for Tenet Healthcare get a modest upward adjustment via an analyst price-target increase.

03

What to watch

Traders may discount the update if Tenet’s fundamentals or guidance have not changed, and if the broader analyst dispersion (e.g., targets up to $342) already reflects a wide range of outcomes.

Relevance 4/10Novelty 4/10Timing: today’s analyst note update

Background

The piece is an analyst-coverage update: Truist reiterates a Buy rating on Tenet Healthcare and increases its price target.

Company-level read

Ticker impact

$THCBullishMedium confidence
Context

Truist Securities maintained Tenet Healthcare at Buy and raised its price target to $305 from $290, implying upside versus the Nov 2 close.

Expected impact

Mild upward bias as traders price in the higher target, with follow-through depending on whether other analysts adjust similarly.

Evidence & confidence

The article provides a specific, time-stamped PT change and reiterates the Buy rating, but it does not include new operational or financial disclosures from Tenet itself.

Market effects

Limited read-through to the broader healthcare services sector because the catalyst is a single-bank target change, not sector-wide guidance or regulation.

Minimal, as the news is US-focused and tied to one issuer’s analyst coverage.

Low, since it does not involve cross-border policy, supply chains, or global capital markets.

Counterpoint

The move may have limited impact if the market already expects similar valuation support, making the PT change more incremental than directional.

Key entities

  • Tenet Healthcare

    Subject of the analyst action, with a Buy rating maintained and price target raised to $305 from $290.

  • Truist Securities

    The brokerage issuing the maintained rating and updated price target.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.